Swainsonine Tridolgosir|cas:72741-87-8|西域试剂

Swainsonine Tridolgosir,98.0%

产品编号：Bellancom-N6722| CAS NO：72741-87-8| 分子式：C₈H₁₅NO₃| 分子量：173.21

Swainsonine 是从紫云英属植物中分离得到的生物碱类，为 α-甘露糖苷酶 (α-mannosidase) 抑制剂，具有抗肿瘤活性。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-N6722		￥3700.00	杭州北京（现货）
Bellancom-N6722		￥11100.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Swainsonine Tridolgosir

产品介绍

Swainsonine (Tridolgosir) 是一种天然的吲哚里西啶生物碱，是一种有效且可逆的 α-甘露糖苷酶（α-mannosidase）抑制剂。Swainsonine 诱导细胞凋亡（apoptosis）和细胞周期停滞在 G2/M 期。Swainsonine 具有抗肿瘤活性。

生物活性

Swainsonine (Tridolgosir) is an natural indolizidine alkaloid, a potent and reversible α-mannosidase inhibitor. Swainsonine induces apoptosis and cell cycle arrest at G2/M phase. Swainsonine shows anti-tumor activity.

体外研究

Swainsonine (0-40 µM; 12 h) shows antiproliferative activity in U251 and LN444 cells.
Swainsonine (30 µM; 12 h) induces apoptosis and cell cycle arrest at G2/M phase, and decreases the expression of CyclinD1 and CDK4 protein levels, increases the expression of p16 protein level.
Swainsonine (30 µM; 12 h) reduces glioma cell migration and invasion.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	U251, LN444 cells
Concentration:	0, 10, 20, 30, 40 µM
Incubation Time:	12 h
Result:	Inhibited cell viability in a dose-dependent manner, and shows no cytotoxicity in normal brain cells.

Cell Cycle Analysis

Cell Line:	U251 cells
Concentration:	30 µM
Incubation Time:	12 h
Result:	Induced cell cycle arrest at G2/M phase.

Apoptosis Analysis

Cell Line:	U251 cells
Concentration:	30 µM
Incubation Time:	12 h
Result:	Induced apoptosis with the cleaved-Caspase-3 and cleaved-Caspase-9 expression were obviously increased.

体内研究
(In Vivo)

Swainsonine (1 mg/kg; i.p.; twice daily for ten days) and cisplatin increases the anti-tumor efficacy in mouse.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Eighty-seven sixty-day-old male C57BL/6 mice
Dosage:	1 mg/kg (cisplatin; 0.25 mg/kg, i.p., every other day for 10 days)
Administration:	I.p.; twice daily for ten days
Result:	Showed a significant reduction in ascites volume of 63.5% was observed in mice and a significant reduction in the percentage of cells in the G0/G1, S and G2 phases.

体内研究

Swainsonine (1 mg/kg; i.p.; twice daily for ten days) and cisplatin increases the anti-tumor efficacy in mouse.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Eighty-seven sixty-day-old male C57BL/6 mice
Dosage:	1 mg/kg (cisplatin; 0.25 mg/kg, i.p., every other day for 10 days)
Administration:	I.p.; twice daily for ten days
Result:	Showed a significant reduction in ascites volume of 63.5% was observed in mice and a significant reduction in the percentage of cells in the G0/G1, S and G2 phases.

体内研究

Swainsonine (1 mg/kg; i.p.; twice daily for ten days) and cisplatin increases the anti-tumor efficacy in mouse.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Eighty-seven sixty-day-old male C57BL/6 mice
Dosage:	1 mg/kg (cisplatin; 0.25 mg/kg, i.p., every other day for 10 days)
Administration:	I.p.; twice daily for ten days
Result:	Showed a significant reduction in ascites volume of 63.5% was observed in mice and a significant reduction in the percentage of cells in the G0/G1, S and G2 phases.

性状

Solid

溶解性数据

In Vitro:

DMSO : 10 mg/mL (57.73 mM; Need ultrasonic and warming)

Ethanol : 10 mg/mL (57.73 mM; Need ultrasonic and warming)

H₂O : 3.57 mg/mL (20.61 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	5.7733 mL	28.8667 mL	57.7334 mL
5 mM	1.1547 mL	5.7733 mL	11.5467 mL
10 mM	0.5773 mL	2.8867 mL	5.7733 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

参考文献

. Dorling PR, et al. Inhibition of lysosomal alpha-mannosidase by swainsonine, an indolizidine alkaloid isolated from Swainsona canescens. Biochem J. 1980 Nov 1;191(2):649-51. [Content Brief]

. Sun L, et al. Swainsonine represses glioma cell proliferation, migration and invasion by reduction of miR-92a expression. BMC Cancer. 2019 Mar 19;19(1):247. doi: 10.1186/s12885-019-5425-7. [Content Brief]

. Santos FM, et al. Increased antitumor efficacy by the combined administration of swainsonine and cisplatin in vivo. Phytomedicine. 2011 Sep 15;18(12):1096-101. [Content Brief]

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

产品编号(Item Number)

批号(Lot Number)

符号	GHS07
信号词	Warning
危害声明	H302-H312-H332
警示性声明	P280
个人防护装备	dust mask type N95 (US);Eyeshields;Gloves
危害码 (欧洲)	Xn: Harmful;
风险声明 (欧洲)	R20/21/22
安全声明 (欧洲)	36
危险品运输编码	NONH for all modes of transport
WGK德国	3
RTECS号	NM2408666
海关编码	29339900

1. 物质的识别

产品名：	Swainsonine
CAS号：	72741-87-8
制造商/供应商：	西域试剂网站：www.hzbp.cn 邮件：13911702513@139.com

2. 合成/成分数据

产品名：	Swainsonine
分子式：	C8H15NO3
分子量：	173.21

3. 急救措施

吸入后：	如果吸入，移至空气新鲜处，如果呼吸困难，给输氧，如呼吸停止，给予人工呼吸。
皮肤接触后：	用大量的水冲洗，移除污染的衣服和鞋子。
眼睛接触后：	检查并取下隐形眼镜，并用大量的水冲洗；呼叫医生。
吞食后：	如果吞食，用大量纯净水漱口；呼叫医生。

4. 消防措施

适当的灭火剂：	雾状水，二氧化碳，干粉或泡沫。
防护设备：	穿戴自给式呼吸器和防护服，以防止与皮肤和眼睛接触。

5. 泄漏应急处理

安全防范措施：	封锁泄漏区域；穿戴自给式呼吸器，防护服和厚橡胶手套。
清洁/收集措施：	使用液体粘合原料（硅藻土，通用粘合剂）吸取精细粉末；使用酒精擦洗表面和设备除去污渍；根据第11条处理被污染的材料。

6. 处理和储存

安全处理说明：	避免吸入和接触皮肤，眼睛及衣物；材料可能略微具有刺激性。
储存：	粉末型式 -20°C 3年；4°C 2年溶于溶剂 -80°C 6个月；-20°C 1个月

7. 接触控制和个人防护

呼吸设备：	NIOSH / MSHA认可的呼吸器。
双手保护：	耐化学腐蚀的橡胶手套。
眼睛防护：	化学安全护目镜。

8. 稳定性和反应活性

稳定性：	按照说明存储是稳定的；避免强氧化剂。
热分解/其他要避免的情况：	避免光和热。

9. 毒性资料

急性毒性：	无可用资料。
主要刺激性影响：	无可用资料。
在皮肤上：	无可用资料。
对眼睛：	无可用资料；可能具有刺激性。